Brain, Vol. 122, No. 6, 1121-1132,
June 1999
© 1999 Oxford University Press
Sequential bilateral transplantation in Parkinson's disease
Effects of the second graft
.
1 Division of Neurology and 2 Division of Neurosurgery, Department of Clinical Neuroscience and 3 Department of Obstetrics and Gynaecology, University Hospital and 4 Division of Neurobiology, Department of Physiology and Neuroscience, University of Lund, Lund, Sweden and 5 University Department of Clinical Neurology and 6 MRC Human Movement and Balance Unit, Institute of Neurology, National Hospital for Neurology and Neurosurgery and 7 MRC Cyclotron Unit, Hammersmith Hospital, London, UK
Correspondence to:
Olle Lindvall, Section of Restorative Neurology, Division of Neurology, Department of Clinical Neuroscience, University Hospital, S-221 85 Lund, Sweden
Five parkinsonian patients who had received implants of human embryonic mesencephalic tissue unilaterally in the striatum 10–56 months earlier were grafted with tissue from four to eight donors into the putamen (four patients) or the putamen plus the caudate nucleus (one patient) on the other side, and were followed for 18–24 months. After 12–18 months, PET showed a mean 85% increase in 6-L-[18F]fluorodopa uptake in the putamen with the second graft, whereas there was no significant further change in the previously transplanted putamen. Two patients exhibited marked additional improvements after their second graft: `on–off' fluctuations virtually disappeared, movement speed increased, and L-dopa could be withdrawn in one patient and reduced by 70% in the other. The improvement in one patient was moderate. Two patients with atypical features, who responded poorly to the first graft, worsened following the second transplantation. These findings indicate that sequential transplantation in patients does not compromise the survival and function of either the first or the second graft. Moreover, putamen grafts that restore fluorodopa uptake to normal levels can give improvements of major therapeutic value.
neural grafting; Parkinson's disease; dopamine; striatum; positron emission tomography
MPTP = 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; UPDRS = Unified Parkinson's Disease Rating Scale
Deceased
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. Carlsson, M. Carta, A. Munoz, B. Mattsson, C. Winkler, D. Kirik, and A. Bjorklund Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration Brain, February 1, 2009; 132(2): 319 - 335. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Carlsson, M. Carta, C. Winkler, A. Bjorklund, and D. Kirik Serotonin Neuron Transplants Exacerbate L-DOPA- Induced Dyskinesias in a Rat Model of Parkinson's Disease J. Neurosci., July 25, 2007; 27(30): 8011 - 8022. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Breysse, T. Carlsson, C. Winkler, A. Bjorklund, and D. Kirik The Functional Impact of the Intrastriatal Dopamine Neuron Grafts in Parkinsonian Rats Is Reduced with Advancing Disease J. Neurosci., May 30, 2007; 27(22): 5849 - 5856. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Master, M. McLeod, and I. Mendez Benefits, risks and ethical considerations in translation of stem cell research to clinical applications in Parkinson's disease J. Med. Ethics, March 1, 2007; 33(3): 169 - 173. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Piccini, N. Pavese, P. Hagell, J. Reimer, A. Bjorklund, W. H. Oertel, N. P. Quinn, D. J. Brooks, and O. Lindvall Factors affecting the clinical outcome after neural transplantation in Parkinson's disease Brain, December 1, 2005; 128(12): 2977 - 2986. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Mendez, R. Sanchez-Pernaute, O. Cooper, A. Vinuela, D. Ferrari, L. Bjorklund, A. Dagher, and O. Isacson Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease Brain, July 1, 2005; 128(7): 1498 - 1510. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y F Tai and P Piccini Applications of positron emission tomography (PET) in neurology J. Neurol. Neurosurg. Psychiatry, May 1, 2004; 75(5): 669 - 676. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Redmond Jr. Book Review: Cellular Replacement Therapy for Parkinson's Disease--Where We Are Today? Neuroscientist, October 1, 2002; 8(5): 457 - 488. [Abstract] [PDF]
|
|
|
|
|
|
K. Mukhida, K. A. Baker, D. Sadi, and I. Mendez Enhancement of Sensorimotor Behavioral Recovery in Hemiparkinsonian Rats with Intrastriatal, Intranigral, and Intrasubthalamic Nucleus Dopaminergic Transplants J. Neurosci., May 15, 2001; 21(10): 3521 - 3530. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Lang Surgery for Parkinson Disease: A Critical Evaluation of the State of the Art Arch Neurol, August 1, 2000; 57(8): 1118 - 1125. [Full Text] [PDF]
|
|
|
|
|
|
P. Brundin, O. Pogarell, P. Hagell, P. Piccini, H. Widner, A. Schrag, A. Kupsch, L. Crabb, P. Odin, B. Gustavii, et al. Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease Brain, July 1, 2000; 123(7): 1380 - 1390. [Abstract] [Full Text] [PDF]
|
|